67912-27-0

Upstream product

• 153381-59-0 3-<1-(phenylhydrazono)-D-erythro-2,3,4-trihydroxybutyl>quinoxalin-2-one 
• 77-78-1 dimethyl sulfate 
• 95-54-5 1,2-diamino-benzene 
• 100-63-0 phenylhydrazine 
• 89-65-6 isoascorbic acid 

Downstream Products

• 142940-65-6 3-(L-2-Acetamido-3,4-diacetoxy-1-phenylhydrazonobutyl)-1-methyl-2(1H)-quinoxalinone 
• 142940-63-4 N-{(R)-2,3-Dihydroxy-1-[(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-(phenyl-hydrazono)-methyl]-propyl}-acetamide 
• 142940-57-6 1-Methyl-3-(L-threo-2,3,4-triacetoxy-1-p-nitrophenylhydrazonobutyl)-2(1H)-quinoxaline 
• 142940-65-6 3-(D-2-Acetamido-3,4-diacetoxy-1-phenylhydrazonobutyl)-1-methyl-2(1H)-quinoxalinone 
• 142940-63-4 N-{(S)-2,3-Dihydroxy-1-[(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-(phenyl-hydrazono)-methyl]-propyl}-acetamide 

Relevant academic research and scientific papers

Addition and cyclisation reactions of sugar phenylhydrazone derivatives via a 1,4-elimination process: preparation of 3-(2-acetamido-1-phenylhydrazonobutyl)-2(1H)-quinoxalinone and 3-(1-acetamidopropyl)-pyrazolquinoxaline (flavazole) derivatives

Acetylation of 3-(L-threo-2,3,4-trihydroxy-1-phenylhydrazonobutyl)-2(1H)-quinoxalinone derivatives (1a and 1c) and of the D-erythro diastereomers (1b and 1d), prepared from L-ascorbic acid and D-isoascorbic acid, respectively, and then treatment of the pr